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Abstract To define relevant disease parameters and their
respective limits indicating the initiation of TNF-α-
blockers in individual patients. Subsequently, to analyze
retrospectively patients with rheumatoid arthritis (RA),
psoriatic arthritis (PsA) or ankylosing spondylitis (AS),
who started TNF-α inhibition in 2006. Points to consider,
regarded relevant for individual treatment decisions as
well as their assessment methods, were ascertained by
experts’ consensus applying the Delphi technique. Subse-
quently, these parameters’ thresholds with respect to the
initiation of a TNF-α-blocker were identified. Thereafter,
the rheumatologists representing 12 centres all over
Austria agreed to retrospectively analyze their patients
s t a r t e do naT N F - α-blocker in 2006. Experts’ opinion
regarding disease parameters relevant to initiate TNF-α-
blockers in RA patients only slightly differed from those
applied in clinical trials, but the parameters’ threshold
values were considerably lower. For PsA patients, some
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DOI 10.1007/s10067-009-1304-ydifferences and for AS patients, considerable differences
between experts’ opinion and clinical studies appeared,
which held also true for decisive parameters’ means and
thresholds. Six hundred and fifty patients, started on TNF-
blockers in 2006, could be analyzed retrospectively, 408
RA patients (53.3 years mean, 340 females), 93 PsA
patients (48.9 years mean, 59 males) and 149 AS patients
AS (42.2 years mean, 108 males), representing approxi-
mately 25% of all Austrian patients initiated on a TNF-
blocker in this respective year. Far more individualized,
patient-oriented treatment approaches, at least in part, are
applied in daily routine compared with those derived from
clinical trials or recommendations from investigative
rheumatologists.
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Abbrevations
SJC Swollen joint count
TJC Tender joint count
DAS28 Disease activity score 28
CRP C-reactive protein
ESR Erythrocyte sedimentation rate
RF Rheumatoid factor
NSAID Non-steroidal anti-inflammatory drug
DMARD Disease-modifying anti-rheumatic drug
BASDAI Bath ankylosing spondylitis disease activity
index
CI Confidence interval
Introduction
In chronic inflammatory joint diseases tumour necrosis
factor-alpha (TNF-α) plays a pivotal role in initiating and
maintaining processes which ultimately lead to cartilage
damage, and bone destruction [1]. Therefore, interfering
with the activity of this cardinal cytokine leads to
significant clinical improvement and to a reduction of
damage respectively [2], which has been shown in
numerous controlled clinical trials. The administration of
the TNF-α inhibitors Etanercept (ETA), Infliximab (IFX)
and Adalimumab (ADA) significantly reduces symptoms
and radiological evident damage as well as improves
function and quality of life in patients with rheumatoid
arthritis (RA), psoriatic arthritis (PsA) and ankylosing
spondylitis (AS) [3–11]. In PsA patients, ETA, IFX and
ADA have been shown to control rash, improve symptoms,
function and quality of life, as well as to retard radiological
evident progression [6–8, 12, 13].
Several international recommendations dealing with the
indication for initiating TNF-inhibitors in patients with
rheumatic diseases have been published [14, 15]. Accord-
ing to an international consensus, TNF-α inhibitors are
recommended for the treatment of severe and active
rheumatoid arthritis after the failure of two disease-
modifying anti-rheumatic drugs (DMARDs) in an adequate
dosage for an adequate duration—unless not tolerated or
contraindicated [14]. For the treatment of ankylosing
spondylitis, the joint assessment in ankylosing spondylitis
(ASAS) and EULAR recommendations consider a patient
with a diagnosis of definite AS to be a candidate for
initiating TNF inhibitors, if at least two non-steroidal anti-
inflammatory drugs (NSAIDs) have previously failed, the
patient has a BASDAI (Bath Ankylosing Spondylitis
Disease Activity Index score) of ≥4, and if a positive
expert’s opinion based on clinical features is present [15].
However, those recommendations have never been
attempted to be validated in daily routine, whether they
really contribute to improved patient care. Expert recom-
mendations, of course, could remarkably improve daily
rheumatology care; though, if they are not disseminated,
discussed and widely accepted, they remain l’art pour l’art.
Since recommendations for the use of TNF-α-blockers
in rheumatic disorders are primarily based on the one hand
on inclusion and exclusion criteria of clinical trials and on
the other on their respective results, they can be regarded
valid, if even, only on the group level. In daily routine,
though, we rarely see that highly active patients usually
included into such studies. Therefore, the question arises to
which extent such recommendations can be transferred to
daily routine, particularly the individual patient’s situation.
Based on this background, it was the aim of this study,
using a Delphi technique among a group of practising
clinical rheumatologists, to decide and quantify parameters,
relevant for treatment decisions in individual patients, with
respect to the initiation of TNF-α-blocker therapy in RA,
PsA and AS first. After having done so, the group agreed to
evaluate routine patients with RA, PsA or AS who
commenced TNF-blocking therapy in 2006 in order to
attempt a validation of the parameters and the respective
thresholds which the group has agreed upon before.
Here, we report the results of this process, which
approached the problem of indicating TNF-blocker therapy
from the situation given in daily routine.
Methods
The working group comprised 13 rheumatologists, repre-
senting 11 rheumatology centres all over Austria, invited by
the convenors (BFL, MH and HB). As a prerequisite, all the
members of the working group had to be involved in
routine patient care. As the first step, the working group
agreed to focus on RA, PsA and AS to define respective
168 Clin Rheumatol (2010) 29:167–174patient profiles for the initiation of TNF-α-blockers and to
employ a Delphi technique to achieve consensus. All
disease-related conditions considered important by each
group member with respect to a therapeutic decision in an
individual RA, PsA or AS patient were gathered first,
regardless whether these were objective, semi-objective or
patient-driven findings.
For RA the number of conditions primarily nominated
totalled to 34, including parameters as profession,
patient’s compliance, co-morbidities, amount of cortico-
steroids necessary/day, and frequency of flares besides the
classical disease activity parameters known from clinical
trials. For AS, 28 parameters were nominated, amongst
them duration of inflammatory back pain, number of days
with inflammatory back pain, enthesitis, social situation
and peripheral arthritis. ForP s A ,a tl a s t2 9c a n d i d a t e
findings could be identified, amongst them life-style,
profession, involvement of little finger joints, compliance
and dactylitis.
At this stage of the process, the group agreed that at least
four parameters meaningful for initiating TNF-blockers had
to be defined by consensus for either RA, AS and PsA. A
parameter would be finally accepted, if it had achieved an
acceptance of 60% by the panel, whereas a parameter, not
or only nominated once during the following Delphi
rounds, was to be withdrawn. Whenever four parameters
would have achieved acceptance, the Delphi procedure was
to be terminated. Subsequently, after having achieved
consensus with respect to the single parameters, their
respective method of assessment was determined applying
the same Delphi technique. As the final step of the process’
first part, the parameters’ lower threshold values referring
to the initiation of TNF-blocking therapy had to be
identified. To this end a consensus meeting was organized
with an attendance rate of 85%. The threshold values for
each single parameter were worked out by voting and
calculating the lower 95% CI for the experts’ opinion’s
mean.
At the end of the consensus meeting, the panellists
agreed upon a retrospective analysis of all their patients
started on a TNF-α-blocker in 2006. The rationale was to
find out whether the parameters revealed by a theoretical
procedure could be regarded valid with respect to their
documentation rate and relevance in daily routine. In
addition, the parameters elaborated by the Delphi-process
should be compared with large clinical trials inclusion
criteria in order to get a picture about the differences
between the clinical trial world and daily routine. Above
all, this analysis should answer the question whether a
situation considered desirable, as expressed by the elabo-
rated key parameters and their threshold values, would
remain preferable after having obtained knowledge about
the real situation.
Results
Three Delphi rounds were necessary to finally identify
eight points-to-consider for the initiation of TNF-blockers
in RA patients, six ones for PsA and four ones for AS
patients, respectively, see Table 1. It took another two
Delphi rounds to elaborate the respective assessment
methods, see also Table 1. The mean participation in the
five Delphi rounds amounted to about 80%.
Regarding the initiation of TNF-α-blockers in RA
patients, the highest degree of congruence between the
experts’ opinion and the literature evidence as indicated by
the inclusion criteria of large clinical trials or by interna-
tional recommendations could be found. Interestingly,
patient’s global assessment, although necessary to calculate
most of the disease activity scores [16–18] constituted no
explicit inclusion criterion in any large clinical trial. With
respect to joint counts, there was strong agreement that a
total joint count is essential for clinical judgement before
any therapeutic change in an individual patient, however,
that a 28 joint count could be regarded sufficient for routine
monitoring [16]. Radiological progression was primarily
nominated as a key point for RA patients, however, later on
defining thresholds, the participants achieved consensus,
that positive evidence for radiological progression would
not be mandatory to consider TNF-blocker therapy.
Subsequently, the documentation rate of radiological
progression was found considerably low during the retro-
spective patient evaluation.
Much more discrepancies occurred with respect to the
management of PsA and AS patients, see also Table 1. For
PsA, enthesitis, dactylitis and spine involvement were
regarded that crucial to be explicitly nominated as key
parameters. In contrast to several clinical trials, failure to
previous NSAID treatment was regarded of less importance
by the panellists, as well as a positive finding for RF [6–8,
12]. Of course the skin disease’s extent constitutes a major
issue for a therapeutic decision in an individual PsA patient.
Although psoriatic skin disease of course constitutes a
dermatological outcome and may warrant anti-TNF therapy
per se, no physician would stop this kind of therapy, if the
patient’s skin cleared up but there was no benefit on the
joints, and subsequently the patient would then be
considered a rheumatological “treatment failure”.
Regarding AS only, the BASDAI was found to be part of
both, namely the inclusion criteria of clinical trials and the
parameter set developed by the group. With the exception
of one study [19], NSAID failure and peripheral arthritis
were no major issues of large clinical trials.
After having agreed upon the key parameters the
elaboration of their respective threshold values constituted
the next step of the process. Those were determined during
another two Delphi rounds (methods of assessment) and the
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prisingly enough, were found to be considerably lower than
the respective ones when those parameters were applied as
inclusion criteria in large clinical trials with TNF-blockers.
The respective values are given in Tables 2, 3 and 4.
Retrospective analysis of patients
At the consensus meeting the group members agreed to
retrospectively analyse their patients, initiated on a TNF-
blocker in 2006 for the first time, in order to answer the
question whether the group’s consensus was in line with
real life in daily routine. Although the panellist were well
aware of the problems implicated with a retrospective
evaluation, this decision was taken in order speed up the
project.
Overall, in the participating centres 650 patients were
started on TNF-inhibiting therapy in 2006. Four hundred
and eight patients with RA (mean age 53.3 years, 340
females), 93 patients with PsA (mean age 48.9 years, 59
males) and 149 patients with AS (mean age 42.2 years,
108 males). This number of patients represents approx-
imately 25% of all Austrian patients initiated on a TNF-
blocker for the first time in this respective year. Given
the number of patients, the different surroundings and
professional settings the panellist are working, these
Rheumatoid arthritis
Parameter Method of assessment
SJC Total joint count
TJC Total joint count
VAS patient global assessment 0–100 mm
DAS DAS28
CRP mg/l; mg/dl
ESR mm/1st hour
DMARDs Failure number+preparation
X-ray progression Yes/no; physician’s assessment
Psoriatic arthritis
Parameter Method of assessment
SJC Total joint count+dactylitis+enthesitis
TJC Total joint count+dactylitis+enthesitis
Degree of skin involvement Likert 0–10, physical assessment
Spine involvement Yes/no; physical assessment
DMARDs failure Number+preparation
X-ray progression Yes/no; physician’s assessment
Ankylosing spondylitis
Parameter Method of assessment
BASDAI 0–10
Failure, response to NSAIDs Number
Positive radiological findings incl. MRI Yes/no; physician’s assessment
Presence and extent of peripheral arthritis SJC+TJC+dactylitis+enthesitis
Table 1 Experts’ points to con-
sider and assessment methods
for initiating TNF inhibitors in
RA, PsA and AS patients
Table 2 Parameters, experts’ mean values and RA patients’ (n=408) mean values
Parameter RA Experts’mean Lower 95% CI Patients’mean Range Percentdocumentation
SJC 1 1 7.03 0–32 86.3
TJC 4 2 9.64 0–49 85.3
VAS patient’s global ass. 43 35 47.61 0–100 87.0
CRP (0.5 normal) 0.5 0.5 1.85 0–13.2 58.8
ESR 15 11 35.41 2–113 91.2
DMARDs failure (n) 2 1 2.47 0–8 93.1
DAS28 (calculated) 3.24 5.02 0.77–8.09 56.1
X-ray No No 57.8% yes No–yes 38.7
170 Clin Rheumatol (2010) 29:167–174patients may be regarded representative for all Austrian
patients, although no information with respect to the
remaining 75% of Austrian anti-TNF-treated patients
was obtained.
Tables 2, 3 and 4 also summarize the mean values and
the respective range for the key parameters, identified in the
patients retrospectively. In addition, their documentation
rate was also ascertained retrospectively and is given in the
respective tables.
The documentation rate for the single parameter’s
documentation differed consistently between the three
diseases. For RA, a 79.7% documentation rate could be
found retrospectively, while it amounted to 64.1% for AS
and to 55.2% for PsA, respectively.
According to the results of this evaluation, the patient
population in general can be regarded severely diseased
[16, 20], however, the respective ranges indicate high
individual variability with respect to disease activity. As it
can be seen in the tables 18.5% of the RA patients, 23.6%
of the PsA patients and 26.3% of the AS patients, did not
even meet the lower limits elaborated by the panel at the
time point TNF-blocking therapy was initiated.
Discussion
Practising rheumatologists from all over Austria participat-
ed in this project with the main purpose to figure out their
strategies with respect to the initiation of TNF-blocking
therapy in single RA, PsA and AS patients. Hence, the key
question at the beginning of the Delphi procedure was:
“What do I regard essential for the decision to initiate a
TNF-blocker in a single patient?”
TNF-blocking agents have proven their efficacy as well
as their tolerability in numerous groups of patients during
clinical trials [3–11]. However, the results of such trials
may only be partially transferable into daily individual
patient care. In clinical routine, not so many patients are as
highly active as those usually included into clinical trials
and additionally, those trial patients somewhat constitute a
distinct group—not easily comparable to clinical routine
regarding e.g. concomitant diseases and medication—given
the restrictive inclusion criteria of clinical trials [4, 21, 22].
A lot of publications are dealing with this situation [23–25].
Thus, this group of practising rheumatologists attempted at
least in part to answer the question which kind of patients
should be treated with TNF-blockers by experts’ consensus
based on their personal experience, on the literature
evidence as well as on their estimation of patients’
perceptions [26]. In Austria, anti-TNF therapy is fully
reimbursed after prescription of a rheumatologist by the
social insurances, if at least one conventional DMARD has
failed; nominal values of any disease activity score of
course are recommended to support the treatment decision,
but they are not obligatory.
As the primary result of this consensus project—not
unexpected—considerabledifferences between daily rheuma-
tologic practise and the world of investigative rheumatology
occurred, as most of the recommendations for the initiation of
anti-TNF therapy—including the Austrian ones—are
deducted from clinical trials [14, 15, 27].
In particular, the great number of parameters quoted at
the beginning of the Delphi process witnesses how
differently rheumatologists approach the assessment of
individual patients in contrast to the necessary uniform
regulations of clinical trials. As expected, the highest
Table 3 Parameters, experts’ mean values and PsA patients’ (n=93) mean values
Parameter PsA Experts’mean Lower 95% CI Patients’mean Range Percentdocumentation
SJC+dactylitis+enthesitis 1 1 5.1 0–22 68.8
TJC+dactylitis+enthesitis 3 2 8.6 0–36 72.0
skin involvement (VAS 0–10) 0.3 0 4 0–10 49.5
DMARDs failure (n) 1 1 1.83 0–5 48.4
X-ray progression No No 51.0% yes No–yes 32.3
Spine involvement No No 29.6% yes No–yes 60.2
Table 4 Parameters, experts’ mean values and AS patients’ (n=149) mean values
Parameter AS Experts’mean Lower 95% CI Patients’mean Range Percentdocumentation
BASDAI 3.6 3.4 5.98 2.63–9.61 66.7
NSAID failure (n) 2 2 2.26 1–5 76.7
Peripheral arthritis 1 1 1.63 0–16 52.7
Positive imaging, incl. MRI Yes Yes 90% yes Yes–no 60.0
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lowest for PsA. Of course the great experience with RA
clinical trials 1994 exerted a great influence on the
rheumatologic community in this respect [3, 28]. The issue
of radiological progression can be regarded an example for
the influence clinical trials may exert. Although primarily
chosen as a key point, there was later consensus that even if
no progression occurs TNF-blockers may be indicated,
suggesting that radiological progression may be of scien-
tific, however, of lower practical worthiness [29, 30].
PublicationsonPsAandASappearedparticularlylaterand
lessfrequent[9, 13]. Therefore, they apparently did not affect
the rheumatologists’ thoughts and attitudes that extensively.
It is of particular interest that no formal evaluation of
functionality and quality of life by a questionnaire was
regarded that important to be included into the key
parameters’ list. [31, 32] With respect to disease activity
assessment, it seems to be that rheumatologists are focused
on joints rather than on functional status and pain as
important measures of disease activity. Concordantly, we
could find a reasonably high documentation rate for joint
counts, which is somewhat different to published data from
other countries [33]. In daily routine, there is always a
battle between the need of documentation and the respec-
tive time requirements. Thus, the refrain from HAQ scores
or SF-36 may be explained by the time needed for their
evaluation. Considering all the parameters chosen by the
clinicians, a focus on time-sparing procedures nevertheless
providing reasonable reliability can be recognized.
Short fully patient administered questionnaires, such as the
Routine Assessment of Patient Index Data 3 or a modified
version of the Rheumatoid Arthritis Disease Activity Index
(RADAI-5) could provide a solution for the problem of
documentation and the time necessary for it [34, 35].
Striking differences between clinical trials and subse-
quent international recommendations elaborated by inves-
tigative rheumatologists on the one hand and the practising
rheumatologists’ opinion on the other, however, were found
with respect to the disease activity thresholds for the
initiation of TNF-blockers [4–15, 27].
In RA clinical trials, the inclusion values for SJC, TJC
and ESR were particularly higher than our experts’ mean
thresholds, which can be regarded in line with recent
publications [23–25].
In patients with PsA or AS, discrepancies not only
regarding the numerical limits, but regarding the decisive
parameters themselves occurred. Inclusion criteria and
scores applied in clinical trials differ considerably [6–8,
36]. Most of the studies included only patients at a rather
high disease activity and severity [6–8]. In studies with AS
patients, conducted before the publication of the ASAS
recommendations for the initiation of TNF-inhibitor therapy
(i.e. BASDAI ≥4 and the failure of at least two NSAIDs)
the failure for at least two NSAIDs did not constitute an
inclusion criterion [9–11, 14].
The rate for the single parameter’sd o c u m e n t a t i o nd i f f e r e d
consistently between the three diseases. For RA patients a
79.7% documentation rate could be found retrospectively,
which can be regarded high enough to justify some
conclusions. For AS patients the documentation rate
amounted to 64.1% and to 55.2% for PsA, respectively,
which may limit the validity of respective deductions.
In this evaluation of roughly 25% of the Austrian TNF-
blocker patients, initiated in 2006, a great number of patients
appeared to be far below the usual thresholds for disease
activity applied in clinical trials. Retrospective analyses are
of course fraught with problems and the results obtained
have to be regarded in this context. The impossibility to
ultimately clarify causalities constitutes one main issue in
this respectas wellas a recall bias one another.Therefore this
retrospective research was not intended to prove but to give
empirical evidence to strengthen the primary hypothesis that
patients in clinical routine are substantially different from
those in clinical trials.
The low thresholds for the decisive parameters elaborat-
ed by expert’s consensus were somewhat surprising and
unexpected primarily. However, as worked out by the
retrospective evaluation of patients, they mirror daily
clinical routine, which has to deal with the individual
patient’s situation. In a very recently published French
paper also 18% of patients with SpA did not fulfil the
national recommendations at the onset of therapy, a result
which can be seen in line with our results [37].
It turned out that in routine care even patients falling
short of these already low limits, are initiated on TNF-
blocking therapy, e.g. with the intention to spare cortico-
steroids. Another major motivation for these prescribing
off-license may be that TNF-blockers are regarded the last
therapeutic choice in a patient with long-standing refractory
disease and multiple treatment failures. In any case, the
individual patient’s situation, which is, as a kind of
loophole, almost always included into recommendations,
plays a great, if not the greatest role in daily routine.
Having said that, the results of the retrospective analysis
also indicate the participating experts’ persuasion that TNF-
blockers may also work in patients at lower disease activity
[38]. Overall, the primary goal for the practising rheuma-
tologist is improvement of the single patient’s situation at
his desk. In this respect patients’ and physicians’ percep-
tions of disease activity changes have been found substan-
tially divergent [39]. Patient dependent features, such as
age, profession, social circumstances, high doses of cortico-
steroids necessary to maintain low disease activity, intoler-
ance of several treatments, severe impairment by an
oligoarticular disease, cannot be part of clinical studies
obviously. However, they constitute major issues in daily
172 Clin Rheumatol (2010) 29:167–174routine highly influencing daily therapeutic decisions,
including the initiation of TNF-blockers.
Thus, for a lot of patient-related reasons, TNF-blockers
are administered in patients at a disease activity stage; those
compounds were not studied for. A thorough evaluation of
these patients’ disease courses, not complying with the
therapeutic recommendations, deems mandatory to prove
the physicians’ intentions in those cases [38].
At the beginning of this project, it was hypothesized that
far more individualized, patient-oriented treatment
approaches are applied in daily routine than in clinical
trials. The results obtained underlined this hypothesis. The
question whether such individual approaches may contrib-
ute to an improvement of our treatment results and
subsequently of our patients’ situation can rather be
answered by observational studies, than by the means of
randomized clinical trials. There was consensus in the
working group that practising rheumatologists should
demand research goals they regard necessary to support
and ease their daily work [40]. Additionally, the panellist
agreed that simple and as uniform as possible, documenta-
tion of patients will finally result in improved patient care.
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